(Q43593551)

25 November 2017

title

SCAP gene polymorphisms decrease the risk of nonalcoholic fatty liver disease in females with metabolic syndrome (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

25 November 2017

1 reference

1 reference

1 reference

Shanshan Sun

1

1 reference

25 November 2017

Miao Wang

2

1 reference

25 November 2017

Haiyan Song

3

1 reference

25 November 2017

Tao Wu

4

1 reference

25 November 2017

Huafeng Wei

5

1 reference

25 November 2017

Songhua He

6

1 reference

25 November 2017

Zhaoguo Ding

7

1 reference

25 November 2017

Guang Ji

8

1 reference

25 November 2017

publication date

1 December 2013

1 reference

25 November 2017

1 reference

25 November 2017

volume

92

1 reference

25 November 2017

issue

3

1 reference

25 November 2017

page(s)

565-570

1 reference

https://scigraph.springernature.com/pub.10.1007/s12041-013-0280-9

25 November 2017

exact match

0 references

cites work

The metabolic syndrome--a new worldwide definition

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Fatty infiltration of liver in hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Dyslipidemia in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Relationship between nonalcoholic fatty liver disease and metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Effects of pravastatin therapy on serum lipids and coronary reactivity are not associated with SREBP cleavage-activating protein polymorphism in healthy young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Genomics and complex liver disease: Challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Blunted feedback suppression of SREBP processing by dietary cholesterol in transgenic mice expressing sterol-resistant SCAP(D443N).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Prevalence of the metabolic syndrome in the Yan-an region of northwest China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Non-alcoholic fatty liver disease and obesity: not all about body mass index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12041-013-0280-9

High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

21 January 2018

1 reference

12 December 2020

Metabolic syndrome and non-alcoholic fatty liver disease.

1 reference

12 December 2020

Nonalcoholic fatty liver disease

1 reference

12 December 2020

Pathology of nonalcoholic fatty liver disease

1 reference

12 December 2020

10.1007/S12041-013-0280-9

Identifiers

DOI

1 reference

25 November 2017

1 reference